Clinical Trial Update: Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Lutathera (177Lu-DOTATATE) in combination with Olaparib for somatostatin receptor–expressing recurrent or relapsed solid t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Glioblastoma
• Medulloblastoma
• Neuroblastoma
• Neuroendocrine Tumors
• Osteosarcoma
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)
• Olaparib (Olaparib)

Snippet

Sponsor: Fundación de investigación HM | Conditions: Solid Tumor Cancer, Medulloblastoma | Phase 1, Phase 2 | Status: RECRUITING